Skip to Content
Rush-Copley Medical Group
Home > Health & Fitness > Healthwise > 5-Alpha Reductase Inhibitors for Prostatitis
5-alpha reductase inhibitors interfere with the effect of male hormones (androgens)
prostate gland, which cause the prostate to become
larger. This stops the growth of the prostate and can even cause it to become
smaller. Stopping the growth of the prostate or reducing its size may help
relieve pain or urination problems caused by
5-alpha reductase inhibitors may be prescribed for men who have prostatitis (especially
chronic prostatitis/pelvic pain syndrome, inflammatory) and who also have moderate
symptoms of prostate enlargement.
Some studies have shown that finasteride can help with symptoms of
prostatitis. But in other studies, finasteride didn't improve symptoms any more
Dutasteride has also been shown to improve symptoms of prostatitis.2
Side effects may include:
It is possible that 5-alpha reductase inhibitors are linked to an increased risk for high-grade prostate cancers. But more research is needed.
See Drug Reference for a full list of side effects. (Drug Reference
is not available in all systems.)
This medicine should not be used by men who plan to father a child, because there is a small chance that the medicine could cause a birth defect. Women who are pregnant or might become pregnant should not handle broken or crushed tablets of finasteride or dutasteride.
5-alpha reductase inhibitors reduce prostate-specific antigen (PSA) levels. Because
PSA levels are used to detect early-stage prostate cancer, men interested in
taking 5-alpha reductase inhibitors might consider the following:
Complete the new medication information form (PDF)new medication information form (PDF)(What is a PDF document?) to help you understand this medication.
Nickel JC (2012). Prostatitis and related conditions, orchitis, and epididymitis. In AJ Wein et al., eds., Campbell-Walsh Urology, 10th ed., vol. 1, pp. 327–356. Philadelphia: Saunders.
Nickel JC, et al. (2011). Dutasteride reduces prostatitis symptoms compared with placebo in men enrolled in the REDUCE study. Journal of Urology, 186(4): 1313–1318.
November 11, 2013
E. Gregory Thompson, MD - Internal Medicine & Christopher G. Wood, MD, FACS - Urology, Oncology
How this information was developed to help you make better health decisions.
To learn more visit Healthwise.org
© 1995-2014 Healthwise, Incorporated. Healthwise, Healthwise for every health decision, and the Healthwise logo are trademarks of Healthwise, Incorporated.
Retrieving newsletters from the Web service...
Sorry, the newsletter Web service is unavailable at this time.
You have signed up for the selected newsletters.
© Copyright 2014 Rush-Copley Medical Center • 2000 Ogden Avenue; Aurora, IL 60504
Main: 630-978-6200 • Physician Referral & Information: 630-978-6700 or 866-4COPLEY (866-426-7539)